^
    Apply
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6 • CD4
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (RITZ) (NCT05735834)
    Phase 3
    International Extranodal Lymphoma Study Group (...
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/21/2024
    Primary completion :
    05/01/2029
    Completion :
    05/01/2029
    MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20
    |
    IL2RA expression
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)
    CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (PRO00037171) (NCT04186520)
    Phase 1/2
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/18/2020
    Primary completion :
    06/30/2026
    Completion :
    06/01/2028
    BCL2
    |
    CAR-20/19-T Cells
    A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878)
    Phase 1/2
    Oncternal Therapeutics, Inc
    Completed
    Last update posted :
    02/12/2025
    Initiation :
    01/03/2018
    Primary completion :
    09/25/2024
    Completion :
    09/25/2024
    BCL2
    |
    Imbruvica (ibrutinib) • zilovertamab (UC-961)
    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/30/2018
    Primary completion :
    06/10/2025
    Completion :
    06/10/2026
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/04/2025
    Initiation :
    12/16/2021
    Primary completion :
    03/29/2024
    Completion :
    06/20/2024
    TP53 • BCL2
    |
    TP53 mutation • CD20 positive
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone acetate • methylprednisolone sodium succinate
    Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCI-2018-00315) (NCT03479268)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/22/2018
    Primary completion :
    06/22/2025
    Completion :
    06/22/2025
    CCND1 • FCER2
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCI-2018-01880) (NCT03884998)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    02/26/2019
    Primary completion :
    07/16/2025
    Completion :
    07/16/2025
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Aliqopa (copanlisib)
    SynKIR-310 for Relapsed/Refractory B-NHL (NCT06544265)
    Phase 1
    Verismo Therapeutics
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    11/01/2024
    Primary completion :
    09/01/2028
    Completion :
    12/01/2028
    BCL2
    AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma (C1763102) (NCT05602363)
    Phase 1
    Carna Biosciences, Inc.
    Recruiting
    Last update posted :
    11/01/2024
    Initiation :
    08/01/2023
    Primary completion :
    09/01/2027
    Completion :
    09/01/2027
    PLCG2
    |
    PLCG2 mutation
    |
    docirbrutinib (AS-1763)
    CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600)
    Phase 1
    Joseph Tuscano
    Active, not recruiting
    Last update posted :
    09/19/2024
    Initiation :
    10/23/2020
    Primary completion :
    12/01/2024
    Completion :
    07/01/2025
    CD20 • CD4
    |
    lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)
    19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers (NCT04464200)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    08/23/2024
    Initiation :
    07/06/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    CD20
    Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773)
    Phase 1
    University of Arizona
    Active, not recruiting
    Last update posted :
    07/11/2024
    Initiation :
    11/29/2016
    Primary completion :
    08/25/2025
    Completion :
    08/25/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    cyclophosphamide • bendamustine • cyclophosphamide intravenous
    A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    12/05/2017
    Primary completion :
    03/29/2024
    Completion :
    11/16/2037
    BCL2
    |
    CD20 expression
    |
    cyclophosphamide • fludarabine IV • MB-106
    An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (NCT04447716)
    Phase 1
    Thomas Jefferson University
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    10/16/2020
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    BCL2
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Riabni (rituximab-arrx)
    Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (BGB-A317-3111-10188-101) (NCT04282018)
    Phase 1/2
    BeiGene
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/25/2020
    Primary completion :
    05/06/2025
    Completion :
    12/31/2025
    MSI
    |
    MSI-H/dMMR
    |
    paclitaxel • Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib) • BGB-10188
    Study of SGR-1505 in Mature B-Cell Neoplasms (SGR-1505-101) (NCT05544019)
    Phase 1
    Schrödinger, Inc.
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    04/10/2023
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2
    |
    SGR-1505
    A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) (NCT04809467)
    Phase 1/2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    09/16/2021
    Primary completion :
    12/15/2024
    Completion :
    12/15/2024
    BCL2 • CCND1 • BCL6
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
    |
    parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
    [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma (LYMFOR) (NCT06125028)
    Phase 3
    Pentixapharm AG
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/15/2025
    Completion :
    06/15/2025
    CXCR4
    |
    CXCR4 expression • CXCR4 positive
    A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NX-5948-301) (NCT05131022)
    Phase 1
    Nurix Therapeutics, Inc.
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/13/2022
    Primary completion :
    12/01/2025
    Completion :
    01/01/2027
    BCL2 • BCL6
    |
    bexobrutideg (NX-5948)
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (NCT06014762)
    Phase 1
    Poseida Therapeutics, Inc.
    Recruiting
    Last update posted :
    06/03/2024
    Initiation :
    04/16/2024
    Primary completion :
    03/01/2029
    Completion :
    03/01/2041
    CD20 • CD5 • FCER2
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    01/25/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2026
    HLA-DRB1
    |
    cyclophosphamide • fludarabine IV • busulfan • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous
    BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. (BCL6-RINHL) (NCT06424379)
    Phase N/A
    Hospices Civils de Lyon
    Active, not recruiting
    Last update posted :
    05/23/2024
    Initiation :
    01/01/2024
    Primary completion :
    06/01/2024
    Completion :
    06/30/2025
    BCL6 • LMO2
    Allo HSCT Using RIC and PTCy for Hematological Diseases (NCT05805605)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    05/01/2023
    Primary completion :
    10/22/2027
    Completion :
    10/22/2028
    NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV
    CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma (NCT06026319)
    Phase 1
    Marcela V. Maus, M.D.,Ph.D.
    Recruiting
    Last update posted :
    04/29/2024
    Initiation :
    10/26/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2028
    CD79B
    |
    cyclophosphamide • fludarabine IV
    Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (NCT04223765)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    11/12/2020
    Primary completion :
    03/22/2028
    Completion :
    03/22/2043
    ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous
    Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (17P.176) (NCT03198026)
    Phase 2
    Sidney Kimmel Cancer Center at Thomas Jefferson...
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    02/20/2018
    Primary completion :
    12/31/2024
    Completion :
    02/20/2031
    CD20
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02992522)
    Phase 1
    Beth Christian
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    02/21/2017
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BCL2
    |
    Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab)
    AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas (NCT06340737)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    03/29/2024
    Primary completion :
    04/01/2031
    Completion :
    04/01/2031
    CD22
    Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    10/29/2012
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    HLA-DRB1
    |
    PD-1 expression
    |
    Promune (agatolimod)
    Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma (NCT04508647)
    Phase 2
    University of Colorado, Denver
    Completed
    Last update posted :
    03/21/2024
    Initiation :
    11/23/2020
    Primary completion :
    07/14/2022
    Completion :
    07/14/2022
    CD20
    |
    Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy)
    First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 (BYON4228.001) (NCT05737628)
    Phase 1
    Byondis B.V.
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    03/04/2024
    Primary completion :
    10/01/2024
    Completion :
    12/01/2025
    CD20
    |
    CD20 expression
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • BYON4228
    A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (NCT05828589)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    06/20/2023
    Primary completion :
    03/01/2026
    Completion :
    10/01/2026
    BCL2
    |
    MYC translocation
    |
    BGB-21447
    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774)
    Phase N/A
    Massive Bio, Inc.
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    01/01/2018
    Primary completion :
    12/01/2026
    Completion :
    06/01/2027
    EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703
    |
    HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
    A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (BELLWAVE-001) (NCT03162536)
    Phase 1/2
    ArQule, Inc., a subsidiary of Merck Sharp & Doh...
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    06/26/2017
    Primary completion :
    09/12/2025
    Completion :
    09/12/2025
    BCL2 • BCL6
    |
    BTK mutation • BCL6 translocation • BTK C481
    |
    nemtabrutinib (MK-1026)
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (NCT05653271)
    Phase 1
    Acepodia Biotech, Inc.
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    01/21/2023
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    CD20 • IFNG • IL6 • TNFA • IL2 • IL10
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma (BrUOG 401) (NCT04792502)
    Phase 2
    Brown University
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    07/14/2022
    Primary completion :
    08/01/2025
    Completion :
    08/01/2027
    CD20
    |
    CD20 expression
    |
    lenalidomide • Lunsumio (mosunetuzumab-axgb)
    A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (BHARAT-1) (NCT05607199)
    Phase 1
    Aurigene Discovery Technologies Limited
    Recruiting
    Last update posted :
    01/31/2024
    Initiation :
    09/16/2022
    Primary completion :
    09/16/2025
    Completion :
    10/16/2026
    IL6 • TNFA • IL1A • CCL3
    |
    AUR-103
    A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma (NCT05929612)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    07/28/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2027
    MALT1
    Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (NCT04659044)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    01/08/2024
    Initiation :
    04/01/2021
    Primary completion :
    04/04/2027
    Completion :
    04/01/2029
    CCND1
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)